4952
E.L. Luzina, A.V. Popov / European Journal of Medicinal Chemistry 44 (2009) 4944–4953
ꢂ
inoculation, the microtiter plates were incubated at 37 C, 5% CO
9
2
,
[16] M.G. Pomper, J.L. Musachio, J. Zhang, U. Scheffel, Y. Zhou, J. Hilton, A. Maini,
R.F. Dannals, D.F. Wong, A.P. Kozikowski, Mol. Imaging 1 (2002) 96–101.
5% air and 100% relative humidity for 24 h prior to addition of
[17] S.S. Chandran, S.R. Banerjee, R.C. Mease, M.G. Pomper, S.R. Denmeade, Cancer
drugs. The drugs were solubilized in dimethyl sulfoxide at 400-fold
the desired final concentration and stored frozen prior use. At the
time of drug addition, an aliquot of frozen concentrate was thawed
and diluted to twice the desired final concentration with complete
Biol. Ther. 7 (2008) 974–982.
[18] Y. Chen, C.A. Foss, Y. Byun, S. Nimmagadda, M. Pullambhatla, J.J. Fox,
M. Castanares, S.E. Lupold, J.W. Babich, R.C. Mease, M.G. Pomper, J. Med. Chem.
51 (2008) 7933–7943.
[
19] C. Barinka, Y. Byun, C.L. Dusich, S.R. Banerjee, Y. Chen, M. Castanares,
A.P. Kozikowski, R.C. Mease, M.G. Pomper, J. Lubkowski, J. Med. Chem. 51
medium containing 50
or half log serial dilutions were made to provide a total five drug
concentrations plus control. Aliquots of 100 L of these different
mg/mL gentamicin. Additional four, 10-folds
(2008) 7737–7743.
[
[
20] J.L. Arias, Molecules 13 (2008) 2340–2369.
21] F. Bunz, Cancer Biol. Ther. 7 (2008) 995–996.
[22] N. Zhang, Y. Yin, S.-J. Xu, W.-S. Chen, Molecules 13 (2008) 1551–1569.
23] W. Ichikawa, Gastric Cancer 9 (2006) 145–155.
24] A.V. Popov, A.N. Pushin, E.L. Luzina, Russ. Chem. Bull. 45 (1996) 482.
25] A.V. Popov, A.N. Pushin, E.L. Luzina, Russ. Chem. Bull. 46 (1997) 1032–1033.
[26] A.V. Popov, A.N. Pushin, E.L. Luzina, Russ. Chem. Bull. 47 (1998) 1232–1233.
[27] A.V. Popov, A.V. Shastin, A.N. Pushin, E.L. Luzina, T.N. Gavrishova, Russ. Chem.
Bull. 48 (1999) 1548–1552.
28] A.V. Popov, A.N. Pushin, E.L. Luzina, Russ. Chem. Bull. 49 (2000) 1202–1206.
[29] Yu.V. Zeifman, E.G. Ter-Gabrielyan, N.P. Gambaryan, I.L. Knunyants, Russ.
Chem. Rev. 53 (1984) 256–273.
30] I.L. Knunyants, G.G. Yakobson, Syntheses of Fluoroorganic Compounds,
Springer-Verlag, Berlin, 1985.
31] S.N. Manjula, N. Malleshappa Noolvi, K. Vipan Parihar, S.A. Manohara Reddy,
V. Ramani, A.K. Gadad, G. Singh, N. Gopalan Kutty, C. Mallikarjuna Rao, Eur. J.
Med. Chem. 44 (2009) 2923–2929.
32] H.M. Abdel-Rahman, M.A. Morsy, J. Enzyme Inhib. Med. Chem. 22 (2007) 57–64.
33] R.K.Y. Zee-Cheng, C.C. Cheng, J. Med. Chem. 22 (1979) 28–32.
[34] K.M. Youssef, E. Al-Abdullah, H. El-Khamees, Med. Chem. Res.11 (2002) 481–503.
m
ꢀ
4
ꢀ5
ꢀ6
ꢀ7
ꢀ8
drugs dilutions (10 , 10 , 10 , 10 and 10 M) were added to
the appropriate microtiter wells already containing 100 L of
[
[
[
m
medium, resulting in the required final drug concentration.
Following drug addition, the plates were incubated for an addi-
ꢂ
tional 48 h at 37 C, 5% CO
2
, 95% air and 100% relative humidity.
L of cold 50%
w/v) TCA (final concentration, 10% TCA) and incubated for 60 min
Cells were fixed in situ by the gentle addition of 50
m
[
(
ꢂ
at 4 C. The supernatant was discarded, and plates were washed
five times with tap water and air dried. Sulforhodamine B (SRB)
[
solution (100 mL) at 0.4% (w/v) in 1% acetic acid was added to each
[
well, and plates were incubated for 10 min at room temperature.
Then staining unbound dye was removed by washing (five times
with 1% acetic acid) and plates were air dried. Bound stain was
subsequently solubilized with 10 mM trizma base, and the absor-
bance was read on an automated plate reader at a wavelength of
[
[
[
35] S. Aiello, G. Wells, E.L. Stone, H. Kadri, R. Bazzi, D.R. Bell, M.F.G. Stevens,
C.S. Matthews, T.D. Bradshaw, A.D. Westwell, J. Med. Chem. 51 (2008)
515 nm. The cytotoxic effects were evaluated and the assay results
and dose-response parameters were calculated as previously
described [86].
[
[
38] O.A. Onuchina, S.A. Zaitsev, V.I. Levina, N.B. Grigor’ev, V.V. Chernyshev,
V.G. Granik, Pharm. Chem. J. 41 (2007) 160–165.
Acknowledgements
[39] N.J. Curtis, Aust. J. Chem. 41 (1988) 585–595.
[
[
[
40] J.W. Janus, J. Chem. Soc. (1955) 3551.
41] Z. Piasek, T. Urbanski, Tetrahedron Lett. (1962) 723–727.
42] I.L. Knunyants, L.S. German, B.L. Dyatkin, Izv. Akad. Nauk SSSR, Ser. Khim.
(1956) 1353–1360 [Bull. Acad. Sci. USSR, Div. Chem. Sci., 5(1956) 1387–1394
We thank the National Cancer Institute (NCI) (Bethesda, MD,
USA) for screening our compounds in human cancer cell lines. We
gratefully acknowledge the technical support of V.V. Fedorov (IPAC
RAS) in preparation of perfluoroisobutene and hexafluoroisobutyric
acid. Our special thanks for a fruitful discussion are addressed to
Drs. A.Yu. Aksinenko and A.N. Pushin (IPAC RAS). Additionally, we
thank Drs. R.J. Gillies (Moffitt Cancer Center, Tampa, FL, USA) and
A.K. Grant (Beth Israel Deaconess Medical Center, Boston, MA, USA)
for references. The synthetic part of this work was supported by the
Russian Foundation for Basic Research (Grant No 98-03-33007).
(Engl. Transl.)].
[
[
43] D.P. Del’tsova, M.P. Krasuskaya, N.P. Gambaryan, I.L. Knunyants, Izv. Akad.
Nauk SSSR, Ser. Khim. (1967) 2086–2088 [Bull. Acad. Sci. USSR, Div. Chem. Sci.,
16(1967) 2005–2007 (Engl. Transl.)].
44] I.L. Knunyants, E.G. Abduganiev, S.T. Kocharyan, M.V. Urushadze, V.A. Livshits,
Yu.E. Aronov, E.M. Rokhlin, Izv. Akad. Nauk SSSR, Ser. Khim. (1971) 110–117
[Bull. Acad. Sci. USSR, Div. Chem. Sci., 20(1971) 93–98 (Engl. Transl.)].
[45] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Adv. Drug Delivery Rev. 23
(1997) 3–25.
[46] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose,
J. Langley, P. Cronise, A. Vaigro-Wolff, J. Natl. Cancer Inst. 83 (1991)
757–766.
Appendix. Supplementary data
[47] M.R. Boyd, K.D. Paull, Drug Dev. Res. 34 (1995) 91–109.
[
[
[
48] M.R. Boyd, Anticancer Drug Dev. Guide (1997) 23–42.
49] G.D. Gray, E. Wickstrom, BioTechniques 21 (1996) 780–782.
50] K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein,
J. Plowman, M.R. Boyd, J. Natl. Cancer Inst. 81 (1989) 1088–1092.
51] J.N. Weinstein, T.G. Myers, P.M. O’Connor, S.H. Friend, A.J. Fornace Jr.,
K.W. Kohn, T. Fojo, S.E. Bates, L.V. Rubinstein, N.L. Anderson, J.K. Buolamwini,
W.W. van Osdol, A.P. Monks, D.A. Scudiero, E.A. Sausville, D.W. Zaharevitz,
B. Bunow, V.N. Viswanadhan, G.S. Johnson, R.E. Wittes, K.D. Paull, Science
(Washington, D.C.) 275 (1997) 343–349.
[
References
[
[
[
[
1] J.-P. Begue, D. Bonnet-Delpon, Actual. Chim. 301–302 (2006) 83–87.
2] J.-P. Begue, D. Bonnet-Delpon, J. Fluorine Chem. 127 (2006) 992–1012.
3] K.L. Kirk, Org. Process Res. Dev. 12 (2008) 305–321.
4] K.L. Kirk, Curr. Top. Med. Chem. 6 (2006) 1447–1456 (Sharjah, United Arab
Emirates).
[52] K.L. Rinehart, Med. Res. Rev. 20 (2000) 1–27.
[53] E.J. Corey, in: K.C. Nicolaou, S.A. Snyder (Eds.), Classics in Total Synthesis II:
More Targets, Strategies, Methods, Wiley-VCH, Weinheim, 2003, pp. 109–136.
[54] D. Fattori, C. Rossi, C.I. Fincham, V. Caciagli, F. Catrambone, P. D’Andrea,
P. Felicetti, M. Gensini, E. Marastoni, R. Nannicini, M. Paris, R. Terracciano,
A. Bressan, S. Giuliani, C.A. Maggi, S. Meini, C. Valenti, L. Quartara, J. Med.
Chem. 50 (2007) 550–565.
[
[
[
5] K.L. Kirk, J. Fluorine Chem. 127 (2006) 1013–1029.
6] K.L. Kirk, Biomed. Chem. (2000) 247–265.
7] K. Mueller, C. Faeh, F. Diederich, Science (Washington, DC, U.S.) 317 (2007)
1
881–1886.
[55] S. Crosignani, P.D. White, B. Linclau, Org. Lett. 4 (2002) 2961–2963.
[56] R. Schobert, S. Siegfried, Synlett (2000) 686–688.
[57] P. Kielbasinski, R. Zurawinski, J. Drabowicz, M. Mikolajczyk, Tetrahedron 44
(1988) 6687–6692.
[
[
8] P. Shah, A.D. Westwell, J. Enzyme Inhib. Med. Chem. 22 (2007) 527–540.
9] A. Strunecka, J. Patocka, P. Connett, J. Appl. Biomed. 2 (2004) 141–150.
10] P. Cozzi, N. Mongelli, A. Suarato, Curr. Med. Chem.: Anticancer Agents 4 (2004)
[
9
3–121.
[58] Y.S. Gol’dberg, E. Abele, I. Kalvins, P.T. Trapentsier, M.V. Shimanskaya,
E. Lukevics, Zh. Org. Khim. 23 (1987) 1561–1563 [J. Org. Chem. USSR 23 (1987)
1403-1404 (Engl. Transl.)].
[59] J.L. Urdiales, P. Morata, I. Nunez De Castro, F. Sanchez-Jimenez, Cancer Lett..
(Shannon, Irel.) 102 (1996) 31–37.
[
[
[
11] C. Isanbor, D. O’Hagan, J. Fluorine Chem. 12 (2006) 303–319.
12] H.L. Yale, J. Med. Pharm. Chem. 1 (1959) 121–133.
13] M. Jagodzinska, F. Huguenot, G. Candiani, M. Zanda, ChemMedChem 4 (2009)
49–51.
[
[
14] V.A. Nair, S.M. Mustafa, M.L. Mohler, S.J. Fisher, J.T. Dalton, D.D. Miller, Tetra-
hedron Lett. 45 (2004) 9475–9477.
15] H. Ohtsu, Z. Xiao, J. Ishida, M. Nagai, H.K. Wang, H. Itokawa, C.Y. Su, C. Shih,
T. Chiand, E. Chang, Y. Lee, M.Y. Tsai, C. Chang, K.H. Lee, J. Med. Chem. 45
[60] R. Huls, C. Detry, Bull. Soc. Roy. Sci. Liege 42 (1973) 73–79.
[61] A.N. Tackie, D. Dwuma-Badu, T. Okarter, J.E. Knapp, D.J. Slatkin, P.L. Schiff Jr.,
Phytochemistry 12 (1973) 2509–2511.
[62] A.N. Tackie, D. Dwuma-Badu, T. Okarter, J.E. Knapp, D.J. Slatkin, P.L. Schiff Jr.,
Lloydia 37 (1974) 1–5.
(
2002) 5037–5042.